Nuvo Research Inc.

Hznp Limited

Zogenix International Limited

Nuvo Pharmaceuticals Inc.

Crescita Therapeutics Inc.

Bradley S Galer

Stephen J Farr

John Michael Newsam

Jagat Singh

Edward Thomas Kisak

Robert Dominic King-Smith

Lisa Marie Grierson

Maria Burian

Jonathan Wilkin

Joseph Zev Shainhouse

Servet Buyuktimkin

Nadir Buyuktimkin

Dominic King-Smith

Parthena Martin

Carl L Faingold

Bret Megargel

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT, 5-HT, 5-HTor sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg/kg/day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg/kg/day, to a maximum of 30 mg/day in a liquid oral dose.

Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)

Provided is a method of treating a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising: determining the patient has been infected with SARS-CoV-2; and administering to the patient a therapeutically effective dose of fenfluramine.

Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of treating and/or reducing the occurrence of respiratory depression caused by an opioid in a human patient or patient population using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of stimulating one or more 5-HTreceptors in the brain of a patient undergoing treatment with an opioid, wherein the patient is at risk of respiratory depression, by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.

Compositions and methods for treating respiratory depression with fenfluramine

The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Foamable formulation

The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.

Treatment of pain with topical diclofenac

Treatment of pain with topical diclofenac compounds

Growing community of inventors

West Chester, PA, United States of America

Bradley S Galer